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Purpose: To overcome cytochrome P450 2D6 (CYP2D6) mediated tamoxifen resistance in postmenopausal early
breast cancer, CYP2D6 phenotype-adjusted tamoxifen dosing in patients with impaired CYP2D6 metabolism and/or
the application of endoxifen, the most potent tamoxifen metabolite, are alternative treatment options. To elucidate
both strategies comprehensively we used a physiologically-based pharmacokinetic (PBPK) modeling approach.
Methods: Firstly simulation of increasing tamoxifen dosages was performed by a virtual clinical trial including
populations of CYP2D6 poor (PM), intermediate (IM) and extensive metabolizers (EM) (N = 8,000). Secondly we
performed PBPK-simulations under consideration of tamoxifen use plus concomitant increasing dosages of
endoxifen (N = 7,000).
Results: Our virtual study demonstrates that dose escalation of tamoxifen in IMs resulted in endoxifen steady-state
plasma concentrations similar to CYP2D6 EMs whereas PMs did not reach EM endoxifen levels. Steady-state plasma
concentrations of tamoxifen, N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen were similar in CYP2D6
IMs and PMs versus EMs using once daily dosing of 20 mg tamoxifen and concomitant CYP2D6 phenotype-adjusted
endoxifen dosing in IMs and PMs (1 mg/d and 3 mg/d, respectively).
Conclusion: In conclusion, we suggest that co-administration of endoxifen in tamoxifen treated early breast cancer
women with impaired CYP2D6 metabolism is a promising alternative to reach plasma concentrations comparable
to CYP2D6 EM patients.
Keywords: Postmenopausal breast cancer; Tamoxifen-endoxifen-combination; CYP2D6 genotype; PBPK modelingIntroduction
The efficacy of the selective estrogen receptor modulator
tamoxifen, the backbone of the treatment of estrogen re-
ceptor positive early breast cancer in postmenopausal
women, is based on its bio-activation to 4-hydroxylated
metabolites by hepatic cytochrome P450 (CYP) enzymes
(Brauch et al. 2009). Its anti-cancer activity is mainly at-
tributed to the (Z)-endoxifen isomer with an almost* Correspondence: stefan.willmann@bayer.com
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in any medium, provided the original work is pidentical anti-estrogenic activity compared to (Z)-4-hydro-
xytamoxifen (4OH-TAM) but 5- to 10-fold higher steady
state plasma concentrations (Css) in patients (Lim et al.
2005; Wu et al. 2009).
Cytochrome P450 2D6 (CYP2D6) is highly polymorphi-
cally expressed in humans and involved in crucial steps of
the formation of endoxifen [Figure 1] (Brauch et al. 2009).
The majority of endoxifen arises from the primary tamoxi-
fen metabolite N-desmethyltamoxifen (NDM-TAM) via 4-
hydroxylation exclusively mediated by CYP2D6 (Desta
et al. 2004). To date, more than one hundred CYP2D6
alleles have been described (http://www.cypalleles.ki.se/
cyp2d6.htm) resulting into four different phenotypes:is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Simplified biotransformation scheme of tamoxifen in man. Tamoxifen is mainly N-demethylated to NDM-TAM and subsequently
4-hydroxylated to endoxifen. A minor pathway proceeds via 4-hydroxylation to 4OH-TAM followed by N-demethylation to endoxifen. The
polymorphic CYP2D6 is involved in crucial steps of the endoxifen formation. Abbreviations used in diagram: cytochrome P450 (CYP), sulfonyltransferase
(SULT), uridine-5′-diphosphoglucuronyltransferase (UGT), tamoxifen (TAM), N-desmethyltamoxifen (NDM), 4-hydroxytamoxifen (4OH), endoxifen (END).
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ity), extensive metabolizers (EM; normal enzyme activ-
ity), intermediate metabolizers (IM; decreased enzyme
activity) and poor metabolizers (PM; abolished enzyme
activity). The CYP2D6 genotype-phenotype concord-
ance rate is excellent which has been extensively studied
(for review see (Zanger and Schwab 2013)). Based on
clinical studies there is an increasing body of evidence
that the in vivo metabolism of tamoxifen in postmeno-
pausal early breast cancer depends on CYP2D6, thereby
altering tamoxifen response (Brauch et al. 2013a, 2013b;
Brauch and Schwab 2013). Patients stratified genetically
into CYP2D6 IMs or PMs using the patient’s germline
DNA showed a significant gene-dose-dependent de-
crease in the formation of endoxifen plasma concentra-
tions compared with EM patients (Borges et al. 2006;
Kiyotani et al. 2010; Mürdter et al. 2011; Lim et al.
2011). For instance, higher endoxifen levels correlated
with a significant reduction of breast cancer recurrence
rate (26%) in the Women’s Healthy Eating and Living
(WHEL) trial (Madlensky et al. 2011), and IM and PM
women were more likely to be in the low endoxifen bot-
tom quintile group with an increased risk for recur-
rence. Moreover, data from a clinical multicenter trial
support the notion that a CYP2D6 genotype-guided
tamoxifen dosing approach significantly rises endoxifen
levels in IM and PM patients by doubling the daily dosefrom 20 mg to 40 mg. Of note, only IMs reach endoxi-
fen levels comparable to those of EM patients receiving
the standard dose (Irvin et al. 2011). Finally, direct ad-
ministration of endoxifen to bypass CYP2D6-dependent
bio-activation and to reduce inter-individual variability
of endoxifen Css levels (Ahmad et al. 2010) may be an
attractive alternative in treatment of postmenopausal
breast cancer.
Physiologically-based pharmacokinetic (PBPK) model-
ing provides a knowledge-based approach to mechanis-
tically describe the pharmacokinetics (PK) as well as the
pharmacodynamics (PD) of drugs (Zhao et al. 2012;
Eissing et al. 2011). Implementing genotype-specific en-
zyme activities (e.g. CYP2D6), PBPK models can be pa-
rameterized to predict the impact of different enzyme
phenotypes on PK as well as PD data (Dickschen et al.
2012). Here, we present a PBPK model-based virtual
clinical trial for CYP2D6 phenotype-dependent dosing of
tamoxifen plus the concomitant use of endoxifen in
early postmenopausal breast cancer. The virtual study
aims to establish a dose algorithm providing similar tam-
oxifen metabolic patterns in CYP2D6 IM or PM versus
EM patients using different dosing strategies. Ultimately,
the PBPK modeling approach offers a new dimension in
providing personalized treatment strategies for tamoxi-
fen in early breast cancer with implications for future
clinical trials.
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Software
The PBPK-models were constructed and coupled by means
of the computational systems biology software platform in-
cluding PK-Sim® 4.2.4 and MoBi® 2.3.5 (Bayer Technology
Services GmbH, Leverkusen, Germany; www.systems-biol-
ogy.com/products).
Population simulations were conducted using the MoBi®
Toolbox for MATLAB® 2.2 (Bayer Technology Services
GmbH, Leverkusen, Germany; www.systems-biology.com/
products with MATLAB® from The MathWorks, Inc.,
Natick, USA; www.mathworks.com/products/matlab).
Virtual clinical trial design
The recently published and validated CYP2D6 phenotype
specific PBPK model describing the formation of endoxi-
fen via tamoxifen in European breast cancer patients was
applied in a virtual clinical trial to establish model based
dose algorithms for CYP2D6 IMs and PMs to achieve
tamoxifen metabolic pattern comparable to CYP2D6 EM
patients (Dickschen et al. 2012). Three different dosing
regimens (see below) were evaluated in the virtual popula-
tions of CYP2D6 EMs, IMs and PMs (N = 1,000, each),
representing the major CYP2D6 phenotypes. The results
of the simulated administration protocols were compared
to corresponding clinical median trough Css level taken
from the literature (Mürdter et al. 2011; Madlensky et al.
2011; Irvin et al. 2011; Gjerde et al. 2010, 2008).
Study group A: tamoxifen standard dose regimen
The standard dose regimen of 20 mg tamoxifen once
daily was simulated for a period of twelve months in all
three CYP2D6 phenotype populations (N = 1,000, each).
Study group B: tamoxifen dose escalation
The recently published genotype-guided tamoxifen dose
escalation regimen for CYP2D6 IMs and PMs (Irvin
et al. 2011) was simulated in 1,000 cases, respectively.
Hence, firstly we simulated four months once daily dos-
ing of 20 mg tamoxifen followed by four months dosing
using 20 mg tamoxifen applied twice daily. Secondly,
four months once daily dosing using 20 mg tamoxifen
followed by four months dosing of 40 mg tamoxifen
once daily was assessed again in IMs and PMs. Finally,
four months once daily dosing of 20 mg tamoxifen
followed by four months once daily dosing using 60 mg
tamoxifen in CYP2D6 PM was investigated by using the
PBPK-model.
Study group C: tamoxifen-endoxifen fixed-dose combination
A novel treatment strategy was used combining a fixed-
dose of the parent drug tamoxifen together with the dif-
ferent dosages of the active metabolite endoxifen in
CYP2D6 IMs and PMs for a period of twelve months.The rationale behind this strategy of concomitant use of
tamoxifen plus endoxifen was to achieve not only similar
plasma levels of endoxifen but also of tamoxifen, NDM-
TAM and 4OH-TAM in IMs and PMs comparable to
CYP2D6 EM patients. In all exploratory simulations, the
standard dose of 20 mg tamoxifen was kept constant
and three concomitant endoxifen doses ranging from
0.5 mg to 1.5 mg once daily were investigated in
CYP2D6 IMs (N = 1,000, each). In CYP2D6 PMs, four
endoxifen doses ranging from 1.0 mg to 4.0 mg once
daily were simulated (N = 1,000, each).
Thus, a total of 15 different simulation protocols for
the three CYP2D6 phenotypic groups were investigated
resulting in simulation data of 15,000 virtual European
female early breast cancer patients. The virtual trial de-
signs investigated are illustrated in Figure 2. From these
simulations median trough Css and percentiles were cal-
culated assuming that data are not normally distributed.
Results
Study group A: tamoxifen standard dose regimen
The previously developed and validated PBPK model de-
scribing the CYP2D6-dependent formation of endoxifen
via tamoxifen (Dickschen et al. 2012) nicely reflects the
phenotype-specific median trough Css of tamoxifen,
NDM-TAM, 4OH-TAM and endoxifen in CYP2D6
EMs, IMs, and PMs [Figure 3] observed in several clin-
ical trials (Mürdter et al. 2011; Madlensky et al. 2011;
Irvin et al. 2011; Gjerde et al. 2010, 2008). In case of the
CYP2D6 IMs experimental data for 4OH-TAM and
endoxifen trough Css show high variability which is
mirrored by our model as well. The PBPK model
parameterization of the CYP2D6 IM phenotype was
based on one functional CYP2D6 allele (acc. to (Mürdter
et al. 2011; Coller et al. 2002)).
Since the PBPK model adequacy is sufficiently assessed,
simulated median trough Css levels of tamoxifen, NDM-
TAM, 4OH-TAM and endoxifen as well as the percentiles
5 and 95 for the CYP2D6 EM phenotype were used as ref-
erence ranges to elucidate alternative dosing regimens of
tamoxifen together with endoxifen in CYP2D6 IMs and
PMs by PBPK simulation.
Study group B: tamoxifen dose escalation
The simulation of tamoxifen dose escalation in CYP2D6
IMs results in increasing median endoxifen trough Css
that reach the dimension of simulated median endoxifen
trough Css in CYP2D6 EMs. These simulation data are
similar to plasma levels of endoxifen quantified in EM pa-
tients in clinical trials [Figures 3 and 4]. Of note, simulated
median endoxifen trough Css following 20 mg tamoxifen
applied twice daily were comparable to those observed in
the multicenter trial of CYP2D6 genotype-guided tamoxi-
fen dosing using an identical dosing regimen (Irvin et al.
Figure 2 Virtual clinical trial design. Study group A: 20 mg/day tamoxifen was simulated over a period of twelve months in CYP2D6 EMs, IMs,
and PMs (N = 1,000 for each phenotype group). Study group B: tamoxifen dose escalation to 20 mg twice daily was simulated for four months
followed by four months dosing of 20 mg/day tamoxifen in CYP2D6 IMs and PMs (N = 1,000, each). Tamoxifen dose escalation to 40 mg/day was
simulated for four months followed by four months dosing of 20 mg/day tamoxifen in CYP2D6 IMs and PMs (N = 1,000, each). Only in CYP2D6
PMs, tamoxifen dose escalation of 60 mg/d was simulated for four months followed by four months dosing of 20 mg/day tamoxifen (N = 1,000).
Study group C: 20 mg/d tamoxifen plus increasing endoxifen dosages were simulated in CYP2D6 IMs and PMs for a period of twelve months
(N = 1,000, each). Abbreviations used in diagram: tamoxifen (TAM), cytochrome P450 2D6 (CYP2D6), extensive metabolizer (EM), intermediate metabolizer
(IM), poor metabolizer (PM), once daily (q.d.), twice daily (b.d.), endoxifen (END).
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CYP2D6 IMs correspond to the 4OH-TAM reference
range in CYP2D6 EMs. However, simulated trough Css
levels of tamoxifen and NDM-TAM significantly exceed
the reference values in CYP2D6 EMs [Figure 4].
Generally, tamoxifen dose escalation in CYP2D6 PMs
increases the median endoxifen trough Css in the PBPK-
model in line with data from a clinical study (Irvin et al.
2011). However, using the three different dose escalation
regimens all simulated median trough Css of endoxifen
are constantly lower compared to the 25th percentile of
the simulated reference endoxifen trough Css in CYP2D6
EMs (PBPK model 25th percentile: 14.08 μg/L). The dose
escalation regimen of 20 mg tamoxifen twice daily and
40 mg tamoxifen once daily even results in median
trough Css of endoxifen (6.8 μg/L; 8.14 μg/L) that only
match the 5th percentile of the simulated reference Css
of endoxifen in CYP2D6 EMs (7.5 μg/L). Simulated4OH-TAM trough Css in CYP2D6 PMs regarding to
both dose escalation regimens (20 mg tamoxifen twice
daily: 3.9 μg/L; 40 mg tamoxifen once daily: 4.5 μg/L)
are similar to the 4OH-TAM reference range (median:
3.8 μg/L) in CYP2D6 EMs, whereas trough Css levels of
tamoxifen and NDM-TAM in CYP2D6 PMs exceed
CYP2D6 EM reference levels up to threefold [Figure 4].
Study group C: tamoxifen-endoxifen fixed dose
combination
A standard oral dose of once-daily 20 mg tamoxifen and
concomitant increasing oral doses of endoxifen were
assessed by PBPK simulation. For both phenotypes,
CYP2D6 IM and PM, the simulation data indicate
that concomitant use of tamoxifen and endoxifen re-
sults in systemic exposure levels of tamoxifen, NDM-
TAM, 4OH-TAM and endoxifen comparable to those
in CYP2D6 EMs.
Figure 3 Results of a virtual clinical trial elucidating tamoxifen standard dose regimen. Box-whisker-plots indicate the percentiles 5, 25,
50, 75, and 95 of the population simulation results. Symbols represent CYP2D6 phenotype-specific plasma concentrations extracted from the
literature of clinical trials performed in postmenopausal early breast cancer women and tamoxifen mono-therapy. Abbreviations used in diagram:
tamoxifen (TAM), N-desmethyltamoxifen (NDM), 4-hydroxytamoxifen (4OH), endoxifen (END), cytochrome P450 2D6 (CYP2D6), extensive metabolizer
(EM), intermediate metabolizer (IM), poor metabolizer (PM).
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1 mg endoxifen applied once daily results in almost identi-
cal median trough Css of tamoxifen, NDM-TAM, 4OH-
TAM, and endoxifen in CYP2D6 IMs versus CYP2D6
EMs. In case of CYP2D6 PMs, the combination of 20 mg
tamoxifen and 3 mg endoxifen reaches similar median
trough Css of tamoxifen, NDM-TAM, 4OH-TAM andFigure 4 Results of a virtual clinical trial elucidating tamoxifen dose e
95 of the population simulation results. Shaded grey areas represent media
CYP2D6 EM levels (acc. to Figure 3) as target concentration ranges for all d
dose escalation of tamoxifen (20 mg twice daily over a period of 4 months
2011) are given as symbols. Abbreviations used in diagram: tamoxifen (TAM)
(END), cytochrome P450 2D6 (CYP2D6), intermediate metabolizer (IM), poor mendoxifen as compared with simulated reference steady-
state EM levels [Figure 5].
Discussion
CYP2D6 phenotype related alteration of endoxifen
plasma levels in tamoxifen treated postmenopausal early
breast cancer women is well established and contributesscalation. Box-whisker-plots indicate the percentiles 5, 25, 50, 75, and
n and the percentiles 5 and 95 of simulated reference steady-state
ose escalation regimens. Corresponding plasma concentrations after
) in breast cancer patients extracted by Irvin WJ, Jr. et al. (Irvin et al.
, N-desmethyltamoxifen (NDM), 4-hydroxytamoxifen (4OH), endoxifen
etabolizer (PM).
Figure 5 Results of a virtual clinical trial for tamoxifen-endoxifen fixed dose combination. Box-whisker-plots indicate the percentiles 5,
25, 50, 75, and 95 of the population simulation results. Shaded grey areas represent median and the percentiles 5 and 95 of simulated reference
steady-state CYP2D6 EM levels (acc. to Figure 3) as target concentration ranges for all fixed-dose combinations. A standard dosage of 20 mg
tamoxifen was used for all simulations. Abbreviations used in diagram: tamoxifen (TAM), N-desmethyltamoxifen (NDM), 4-hydroxytamoxifen (4OH),
endoxifen (END), cytochrome P450 2D6 (CYP2D6), intermediate metabolizer (IM), poor metabolizer (PM), fixed-dose combination (FDC).
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2010; Mürdter et al. 2011; Lim et al. 2011; Madlensky
et al. 2011). To overcome an increased risk for breast
cancer recurrence in CYP2D6 variant patients two differ-
ent approaches have been suggested (i) CYP2D6
phenotype-adjusted tamoxifen dosage in CYP2D6 IMs
and PMs to achieve similar endoxifen Css compared with
EMs and (ii) direct administration of the active metabol-
ite endoxifen which ensures independence from the
CYP2D6 polymorphism.
Recently the feasibility of dose adjustment in early
breast cancer women was demonstrated by several studies
using increasing tamoxifen daily dosages from 20 up to
40 mg in IM and PM patients (Irvin et al. 2011; Barginear
et al. 2011; Kiyotani et al. 2012). Whereas in IMs the
endoxifen levels reached almost similar concentrationscompared to EMs, endoxifen plasma levels in PMs were
still significantly lower. This indicates that at least in PMs
the concept of dose escalation of tamoxifen up to 40 mg
does not seem to be an appropriate alternative in clinical
practice.
The sole administration of oral endoxifen instead of
tamoxifen appears to be safe and was well tolerated in a
first-in-man study. Endoxifen is rapidly absorbed and
systemically available as shown exemplarily for the dose
range of 0.5 to 4.0 mg (Ahmad et al. 2010). Currently
some clinical phase 1 trials are ongoing elucidating the
use of endoxifen in adults with refractory hormone
receptor-positive breast cancer, desmoid tumors, gyne-
cologic tumors, or other hormone receptor-positive solid
tumors (ClinicalTrials.gov Identifier: NCT01273168; last
access date Nov 18, 2013) or in patients with metastatic
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Trials.gov Identifier: NCT01327781; last access date Nov
18, 2013). Nevertheless, such an approach neglects the
fact that intermediary metabolites like NDM-TAM and
4OH-TAM or even tamoxifen may have own anti-
estrogenic activity, thereby contributing to the anti-
tumoral effects of tamoxifen in vitro and in vivo (Coezy
et al. 1982; Maximov et al. 2013).
Therefore, we aimed to establish robust and valid dos-
age algorithms by a PBPK modeling approach using dif-
ferent virtual trial designs to provide similar tamoxifen
metabolic patterns in CYP2D6 IM or PM versus EM
patients.
The methodology of PBPK modeling and its increas-
ingly important role in drug development has been ex-
tensively reviewed during the past few years (Huang and
Rowland 2012; Leong et al. 2012). The mechanistic and
knowledge-based approach of PBPK modeling enables
simulations and predictions providing insight into sce-
narios faster, cheaper, or easier than experimentally feas-
ible (Edginton et al. 2006; Willmann et al. 2009). The
impact of PBPK modeling in clinical decision support
for selected populations are extensively outlined recently
(Zhao et al. 2012; Lippert et al. 2012), including PK pre-
diction for liver cirrhotic patients and children (Edginton
and Willmann 2008; Kersting et al. 2012; Willmann et al.
2013). Furthermore, the impact of CYP2D6 pharmacogen-
omics on PK has been studied as well for codeine, a clas-
sical CYP2D6 substrate, using a mechanistic PBPK-model
(Willmann et al. 2009; Eissing et al. 2012).
Our PBPK simulation experiments of increasing tam-
oxifen dosages in CYP2D6 PMs and IMs demonstrated
that dose escalation of tamoxifen to 20 mg twice daily is
only sufficient in CYP2D6 IMs in order to attain a me-
dian endoxifen Css comparable to CYP2D6 EM levels.
These simulation data are in line with experimental data
from a tamoxifen dose escalation trial in early breast
cancer women by Irvine et al. (Irvin et al. 2011) corrob-
orating the validity of our PBPK modeling approach.
However in CYP2D6 PMs dose escalation of tamoxifen
to 20 mg twice daily is not sufficient to reach the median
endoxifen Css simulated and observed in CYP2D6 EMs.
Virtual dose escalation even up to 60 mg tamoxifen once
daily indicates that comparable median CYP2D6 EM
endoxifen Css levels will not be achieved supporting the
predominant role of CYP2D6 in the formation of
endoxifen.
Although tamoxifen is well tolerated it remains un-
clear on whether high doses of tamoxifen may result in
long-term detrimental effects like an increased risk for
endometrial cancer or thromboembolic event. For in-
stance it has been reported that high dose tamoxifen in
the management of various cancers is associated with se-
vere side effects or even increased mortality (Decaudinet al. 2004; Puchner et al. 2004; Bourla et al. 2007). Of
note, our simulation data of tamoxifen dose escalation in
CYP2D6 IMs and PMs indicate that plasma levels of
tamoxifen as well as NDM-TAM are 3-times higher
compared to levels in CYP2D6 EMs using 20 mg tam-
oxifen standard dosage. These simulated plasma levels
are in line with data reported in patients using standard
tamoxifen therapy independent from ethnicity (Mürdter
et al. 2011; Lim et al. 2011; Kiyotani et al. 2012). Al-
though the evidence is lacking that long-term side ef-
fects of tamoxifen treatment are directly linked to
elevated tamoxifen metabolite levels (e.g. NDM-TAM),
the strategy of dose escalation of tamoxifen, preferable
in CYP2D6 IMs, needs further evaluation.
Since short-cutting of tamoxifen adjuvant endocrine
therapy by direct administration of endoxifen might re-
sult in missing beneficial effects of tamoxifen itself and
primary metabolites (Maximov et al. 2013), we next simu-
lated a concomitant administration of tamoxifen standard
dosage (20 mg/d) plus increasing dosages of endoxifen by
the PBPK model. Using fixed-dose combinations we estab-
lished an optimal dose algorithm for European female
CYP2D6 IMs and PMs to achieve a comparable pattern of
tamoxifen metabolite levels compared to CYP2D6 EMs.
Interestingly, CYP2D6 IMs displayed similar Css of tamoxi-
fen, NDM-TAM, 4OH-TAM, and endoxifen when receiv-
ing a fixed-dose combination of 20 mg tamoxifen plus
1 mg endoxifen once daily. In contrast 20 mg tamoxifen
plus 3 mg endoxifen are required in CYP2D6 PMs to
achieve similar plasma levels of tamoxifen, NDM-TAM,
4OH-TAM, and endoxifen as compared with EMs.
Conclusion
Taken together, data from our virtual clinical trial exem-
plarily demonstrate how PBPK modeling can be used as a
valid tool to gain deeper insight into pharmacokinetic prop-
erties of tamoxifen and its metabolites in early breast can-
cer patients. The simulation data indicate a novel dosing
strategy of concomitant use of tamoxifen standard dosage
plus CYP2D6 phenotype-adjusted endoxifen dosing as a
feasible approach to overcome differences in tamoxifen
metabolite levels. Thus, the tamoxifen-plus-endoxifen ap-
proach versus tamoxifen or endoxifen monotherapy offers
a new avenue in treatment of early breast cancer women.
Future proof-of-concept clinical trials are warranted.
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